[go: up one dir, main page]

AR129413A2 - SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE - Google Patents

SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE

Info

Publication number
AR129413A2
AR129413A2 ARP230101296A ARP230101296A AR129413A2 AR 129413 A2 AR129413 A2 AR 129413A2 AR P230101296 A ARP230101296 A AR P230101296A AR P230101296 A ARP230101296 A AR P230101296A AR 129413 A2 AR129413 A2 AR 129413A2
Authority
AR
Argentina
Prior art keywords
drug conjugates
methods
antibody
drug
splicing modulator
Prior art date
Application number
ARP230101296A
Other languages
Spanish (es)
Inventor
Ermira Pazolli
Silvia Buonamici
Thiwanka Samarakoon
Sudeep Prajapati
Nathan Fishkin
James Palacino
Michael Seiler
Ping Zhu
Andrew Cook
Peter Smith
Xiang Liu
Shelby Ellery
Dominic Reynolds
Lihua Yu
Jeremy Wu
Shouyong Peng
Nicholas Calandra
Megan Sheehan
Yonghong Xiao
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of AR129413A2 publication Critical patent/AR129413A2/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se divulgan compuestos de enlazador-fármaco y conjugados anticuerpo-fármaco que se unen a blancos de oncología humana. Los compuestos de enlazador-fármaco y los conjugados anticuerpo-fármaco comprenden un resto farmacológico de modulador de empalme. La divulgación además se refiere a métodos y composiciones para usar en el tratamiento de trastornos neoplásicos administrando los conjugados anticuerpo-fármaco proporcionados en la presente.Disclosed are linker-drug compounds and antibody-drug conjugates that bind to human oncology targets. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in treating neoplastic disorders by administering the antibody-drug conjugates provided herein.

ARP230101296A 2018-06-01 2023-05-23 SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE AR129413A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862679631P 2018-06-01 2018-06-01
US202062679672P 2020-06-01 2020-06-01
US202062779324P 2020-12-13 2020-12-13

Publications (1)

Publication Number Publication Date
AR129413A2 true AR129413A2 (en) 2024-08-21

Family

ID=92542021

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230101296A AR129413A2 (en) 2018-06-01 2023-05-23 SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE

Country Status (1)

Country Link
AR (1) AR129413A2 (en)

Similar Documents

Publication Publication Date Title
CL2024001239A1 (en) Splicing-modulating antibody-drug conjugates and methods of use.
CL2021001534A1 (en) Herboxydiene of antibody-drug conjugates and methods of use.
CL2021000049A1 (en) Eribulin-Based Drug-Antibody Conjugates and Methods for Their Use (Divisional Application 2456-2018)
MX2019008208A (en) METHODS TO TREAT CANCER WITH ANTI-TIM-3 ANTIBODIES.
UY39188A (en) IMIDAZOPYRIDAZINES AS IL-17 MODULATORS
CR20160271A (en) PEPTIDOMETIC COMPOUNDS AND THEIR ANTIBODY-DRUG CONJUGATES
CO2022007924A2 (en) Anti-mesothelin eribulin antibody drug conjugates and methods of use
CO2022003703A2 (en) therapeutic conjugates
CO2020016151A2 (en) Anti-sez6 Antibody-Drug Conjugates and Methods of Use
MX2020010110A (en) DRUG CONJUGATES OF CMET MONOCLONAL BINDING AGENTS, AND USES THEREOF.
AR129413A2 (en) SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
AR117589A1 (en) SPLIT-DRUG MODULATOR ANTIBODY CONJUGATES AND METHODS OF USE
AR117686A1 (en) HERBOXIDIENE SPLIT MODULATOR OF ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
CO2023008051A2 (en) Anti-cd48 antibodies, antibody-drug conjugates, and uses thereof
AR129382A1 (en) BCL-XL AND MET INHIBITORS ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
EA202092951A1 (en) ANTIBODY AND DRUG CONJUGATES AS A SPLICING MODULATOR AND METHODS OF THEIR APPLICATION
AR098781A1 (en) PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES OF THE SAME